PYXIS ONCOLOGY INC (PYXS) Stock Overview
USA - NASDAQ:PYXS - US7473241013 - Common Stock
PYXS Key Statistics, Chart & Performance
The current stock price of PYXS is 3.46 USD. In the past month the price increased by 61.68%. In the past year, price decreased by -5.46%.
PYXS Latest News, Press Relases and Analysis
PYXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About PYXS
Company Profile
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Company Info
PYXIS ONCOLOGY INC
321 Harrison Avenue
Boston MASSACHUSETTS US
Employees: 44
Phone: 16172219059
PYXIS ONCOLOGY INC / PYXS FAQ
What does PYXS do?
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
What is the current price of PYXS stock?
The current stock price of PYXS is 3.46 USD. The price increased by 2.37% in the last trading session.
What is the dividend status of PYXIS ONCOLOGY INC?
PYXS does not pay a dividend.
What is the ChartMill rating of PYXIS ONCOLOGY INC stock?
PYXS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy PYXS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PYXS.
What is the employee count for PYXS stock?
PYXIS ONCOLOGY INC (PYXS) currently has 44 employees.
What is PYXIS ONCOLOGY INC worth?
PYXIS ONCOLOGY INC (PYXS) has a market capitalization of 214.59M USD. This makes PYXS a Micro Cap stock.
PYXS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PYXS. When comparing the yearly performance of all stocks, PYXS is one of the better performing stocks in the market, outperforming 95.39% of all stocks.
PYXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PYXS. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PYXS Financial Highlights
Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -0.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.14% | ||
| ROE | -109.86% | ||
| Debt/Equity | 0 |
PYXS Forecast & Estimates
14 analysts have analysed PYXS and the average price target is 6.12 USD. This implies a price increase of 76.88% is expected in the next year compared to the current price of 3.46.
For the next year, analysts expect an EPS growth of -37.43% and a revenue growth -79.63% for PYXS